Natalie Bennett

Natalie Bennett is HEOR/HTA Lead at Novartis UK, where she leads a team of HEOR managers shaping evidence, HTA and reimbursement strategy for innovative medicines. She has more than 20 years' experience in the pharmaceutical industry, including over 13 years in HEOR, HTA and market access. Natalie has led nine successful HTAs across NICE (including Highly Specialised Technologies and Cancer Drugs Fund-related processes), SMC and AWMSG. These include the first appraisal in the NICE HST process to go straight to final guidance, for a gene therapy in rare disease. She has worked at country level across the UK, Ireland and the Nordics, and internationally with Servier in Paris. NICE invited her to contribute to its HTA Labs project on capturing implementation costs. She holds an MSc in Economic Evaluation in Healthcare (Distinction) from City, University of London.